InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021
May 04 2021 - 7:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company
developing cannabinoid-based pharmaceutical drug candidates and
leading the clinical development of cannabinol (“CBN”), today
announced that Eric. A. Adams, President and CEO of InMed, will be
presenting at Canaccord Genuity’s 5th Annual Global Cannabis
Conference on Tuesday, May 11th, which is being held virtually this
year. Details on the conference and how to participate are below.
Conference Details
Date: Tuesday,
May 11th, 2021 Presentation Details: Tuesday, May
11th at 2:30-2:55pm EDT Presentation Link:
https://wsw.com/webcast/canaccord55/inm/2252448
Eric A. Adams and Bruce Colwill, InMed’s Chief
Financial Officer, will also be conducting 1x1 meetings throughout
the conference with institutional investor groups and family
offices. In order to schedule a meeting, please do so through the
conference portal or reach out to info@inmedpharma.com. Information
on this event will also be posted on InMed’s event page, which can
be found at: www.inmedpharma.com/about/events.
About InMed: InMed
Pharmaceuticals is a clinical-stage company developing a pipeline
of cannabinoid-based pharmaceutical drug candidates, initially
focused on the therapeutic benefits of cannabinol (“CBN”), in
diseases with high unmet medical need. The Company is dedicated to
delivering new therapeutic alternatives to patients that may
benefit from cannabinoid-based pharmaceutical drugs. For more
information, visit www.inmedpharma.com.
Investor Contact: Edison GroupJoe Green/Laine
YonkerT: +1.646.653.7030/+1.646.653.7035E:
jgreen@edisongroup.com / lyonker@edisongroup.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: presenting at Canaccord Genuity’s 5th
Annual Global Cannabis Conference; leading the way in the clinical
development of cannabinol (CBN); developing a pipeline of
cannabinoid-based medications in diseases with high unmet medical
need; and delivering new therapeutic alternatives to patients that
may benefit from cannabinoid-based medicines.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Aug 2024 to Sep 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Sep 2023 to Sep 2024